ArticleJACC. Case reports2026
Feasibility of Robotic Hybrid CABG and Transcarotid TAVI for Severe Aortic Stenosis and Coronary Disease.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManaging severe aortic stenosis and multivessel coronary disease is challenging in patients with elevated surgical risk and hostile iliofemoral anatomy. CASE SUMMARY: A 70-year-old man with severe aortic stenosis, multivessel coronary disease, and advanced peripheral artery disease presented with decompensated heart failure. Given prohibitive transfemoral access and elevated surgical risk, a single-admission staged hybrid strategy was pursued. The patient underwent robotic hybrid coronary aortic bypass grafting (RHCABG), followed 48 hours later by transcarotid transcatheter aortic valve implantation (TAVI). Both procedures succeeded, yielding an uncomplicated recovery and marked functional improvement. DISCUSSION: This case demonstrates the feasibility of combining RHCABG with alternative-access transcatheter valve replacement for high-risk patients unsuitable for conventional surgery. TAKE-HOME MESSAGES: Combining RHCABG and transcarotid TAVI is feasible for high-risk patients. Transcarotid access is a valuable TAVI alternative given hostile iliofemoral anatomy. Single-admission staged hybrid procedures may reduce overall morbidity and recovery time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.